Capvaxive (V116) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Capvaxive (V116) / Merck (MSD)
2021-006679-41: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced Adults Studio clinico per valutare la sicurezza, la tollerabilità e l'immunogenicità di V116 in adulti che hanno già ricevuto la vaccinazione

Not yet recruiting
3
700
Europe
-, Vaccino coniugato pneumococcico 21-valente, [-], [V116], Solution for injection in pre-filled syringe, Suspension for injection in pre-filled syringe, PNEUMOVAX® 23 (pneumococcal vaccine polyvalent), VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)
MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal disease Malattia pneumococcica, Pneumococcal Disease Malattia pneumococcica, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2021-006710-36: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV

Not yet recruiting
3
300
Europe
Pneumococcal 21-Valent Conjugate Vaccine, V116, Solution for injection in pre-filled syringe, Suspension for injection in pre-filled syringe, PNEUMOVAX® 23 (pneumococcal vaccine polyvalent), VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal disease, Pneumococcal disease, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05420961 / 2021-006679-41: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Completed
3
717
Europe, Canada, Japan, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, PCV15, VAXNEUVANCE™, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumonia, Pneumococcal
05/23
05/23
STRIDE-3, NCT05425732 / 2022-000258-27: Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, )

Completed
3
2663
Europe, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, PCV20, Prevnar 20™, APEXXNAR™
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal Infection
05/23
05/23
STRIDE-9, NCT05633992: Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, )

Completed
3
450
Japan
V116, Pneumococcal 21-valent Conjugate Vaccine, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Disease
05/23
05/23
STRIDE-4, NCT05464420 / 2022-000265-41: A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, )

Completed
3
2162
Europe, Canada, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Disease
05/23
05/23
2022-000258-27: Safety and immunogenicity of V116 in pneumococcal vaccine-naïve adults

Not yet recruiting
3
2600
Europe
Pneumococcal 21-Valent Conjugate Vaccine, V116, Solution for injection in pre-filled syringe, Suspension for injection in pre-filled syringe, PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine), Apexxnar, Suspension for injection in pre-filled syringe Pneumococcal pliysaccharide conjugate vaccine (20-valent, adsorbed)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal infection, Pneumococcal infection, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT05526716: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Completed
3
1080
US
V116, QIV, Matching Placebo for V116
Merck Sharp & Dohme LLC
Pneumonia, Pneumococcal
06/23
06/23
STRIDE-7, NCT05393037 / 2021-006710-36: Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, )

Completed
3
313
Europe, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, Placebo, PCV15, VAXNEUVANCE™;, PPSV23, PNEUMOVAX™23, PCV15 - Part B, VAXNEUVANCE™
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal Disease
07/23
01/24
STRIDE-10, NCT05569954 / 2022-001785-35: Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, )

Completed
3
1484
Europe, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Disease
10/23
02/25
STRIDE-13, NCT06177912: A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

Active, not recruiting
3
820
Europe, Canada, Japan, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Infection
02/25
02/25
STRIDE-8, NCT05696080: Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Completed
3
518
Europe, Canada, Japan, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, Placebo, PCV15, VAXNEUVANCE™, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Infection
02/24
02/24

Download Options